Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.

NCT06590857 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Metastatic Breast Cancer
HER2-negative Breast Cancer
ER+ Breast Cancer
Advanced Breast Cancer

Interventions

DRUG: RYZ101

Sponsor

RayzeBio, Inc.